1. Home
  2. Companies
  3. RAD
  4. Material Events

Radiopharm Theranostics (ASX:RAD) — Material Events

ASX:RAD · 21 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Significant 20 articles Notable 1 article Not Assessed 0 articles
Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed
Significant Score 75–89
20
Radiopharm Theranostics Accelerates Trials with FDA Fast Track and Strong Cash PositionMedium
Radiopharm Theranostics advances clinical pipeline with FDA Fast Track, dose escalation, and strong cash position
29 July 2025 ·Quarterly Activities & Cash Report ·85
Radiopharm’s RAD 101 Hits 92% Concordance in Brain Metastases TrialMedium
Radiopharm Theranostics' RAD 101 achieves 92% concordance with MRI in Phase 2b brain metastases trial
15 Dec 2025 ·Clinical Trial Interim Results ·85
Radiopharm Theranostics Hits 90% Concordance in Brain Metastases Imaging TrialMedium
Radiopharm Theranostics Reports 90% Concordance in Phase 2b Trial of RAD 101 for Brain Metastases
24 Mar 2026 ·Clinical Trial Update ·85
Radiopharm Theranostics Advances Brain Cancer Imaging with 92% MRI ConcordanceMedium
Radiopharm Theranostics reports positive Phase 2b interim data, advances multiple clinical trials, and secures $34.5M cash runway into 2027
28 Jan 2026 ·Quarterly Activities & Cash Report ·85
Radiopharm Theranostics Advances Clinical Pipeline Amid Rising Losses and $35M Capital RaiseMedium
Radiopharm Theranostics reports increased loss, advances multiple clinical trials, and completes $35M capital raise
27 Feb 2026 ·Interim Financial Report ·85
Radiopharm Theranostics Launches First Human Trial of Novel Prostate Cancer TherapyMedium
Radiopharm Theranostics Gets Approval to Start Phase 1 Trial of RAD 402 in Advanced Prostate Cancer
18 Nov 2025 ·Clinical Trial Initiation Announcement ·85
Radiopharm Theranostics and Siemens Healthineers Partner to Supply RAD101 for Phase 3 Brain Metastases TrialMedium
Radiopharm Theranostics and Siemens Healthineers partner to supply RAD101 for Phase 3 brain metastases trial
7 Apr 2026 ·ASX Announcement ·85
Radiopharm Secures FDA Nod to Launch First-in-Human Trial of RV-01 Targeting Aggressive TumorsMedium
Radiopharm Theranostics Gets FDA IND Clearance for Phase I Trial of RV-01 Targeting B7-H3 in Solid Tumors
28 July 2025 ·Regulatory Approval Announcement ·85
Radiopharm Theranostics Advances Clinical Pipeline with $40M Capital BoostHigh
Radiopharm Theranostics advances clinical pipeline, secures A$40M funding, and appoints leading oncologist
28 Oct 2025 ·Quarterly Activities and Cash Flow Report ·85
Radiopharm's 177Lu-RAD202 Shows Promising Safety and Tumor Uptake in Early HER2+ TrialMedium
Radiopharm Theranostics Reports Positive Phase 1 Trial Results for 177Lu-RAD202 in HER2+ Tumors
20 Apr 2026 ·Clinical Trial Update ·85
Radiopharm Theranostics Doses First Patient in Pioneering BetaBart TrialMedium
Radiopharm Theranostics doses first patient in Phase 1/2a trial of BetaBart radiotherapeutic
24 Feb 2026 ·Clinical Trial Update ·85
Radiopharm Theranostics Secures A$40M to Advance Clinical PipelineMedium
Radiopharm Theranostics raises A$35M placement, launches A$5M Share Purchase Plan with attaching options
20 Oct 2025 ·Capital Raising ·85
Radiopharm Completes Phase 2b Trial for RAD 101 with 90% MRI ConcordanceMedium
Radiopharm Completes Phase 2b Trial Enrollment for RAD 101 Brain Metastases Imaging; Plans Phase 3
16 Apr 2026 ·Clinical Trial Update ·80
Radiopharm Launches $40M Equity Raise to Accelerate Clinical TrialsMedium
Radiopharm launches A$40M equity raise with SPP and placement to fund clinical programs
20 Oct 2025 ·Prospectus ·80
Radiopharm Theranostics Doses First Patient in RAD 402 Trial for Advanced Prostate CancerMedium
Radiopharm Theranostics initiates Phase 1 trial of RAD 402 in advanced prostate cancer
27 Mar 2026 ·Clinical Trial Update ·80
Radiopharm Theranostics Accelerates Dose in Phase 1 Trial After Safety NodMedium
Radiopharm Theranostics Advances Phase 1 Trial of 177Lu-RAD202 with Higher Dose Following Positive Safety Review
1 Oct 2025 ·Clinical Trial Update ·80
Radiopharm Theranostics Advances 177Lu-RAD204 Trial with Higher Dose ApprovalMedium
Radiopharm Theranostics advances Phase 1 trial of 177Lu-RAD204 with dose escalation to 90mCi
12 Nov 2025 ·Clinical Trial Update ·80
Radiopharm Theranostics Hits 50% Enrollment in RAD101 Brain Metastases TrialMedium
Radiopharm Theranostics Hits 50% Enrollment in Phase 2b RAD101 Brain Metastases Imaging Trial
17 Nov 2025 ·Clinical Trial Update ·80
Radiopharm Theranostics Advances Multiple Trials Amid $14.9M Quarterly Cash BurnMedium
Radiopharm Theranostics advances clinical trials, reports $19.2M cash with $14.9M quarterly burn
23 Apr 2026 ·Quarterly Activities and Cash Flow Report ·75
Radiopharm Theranostics Advances Phase 1 Trial of 177Lu-RAD202 to Next Dose LevelMedium
Radiopharm Theranostics Advances Phase 1 Trial of 177Lu-RAD202 to Next Dose Level
8 Apr 2026 ·Clinical Trial Update ·75
Not Assessed Low Score, or missing data
0

No articles in this tier for the last 12 months.